Steward Partners Investment Advisory LLC Buys Shares of 2,770 Hims & Hers Health, Inc. (NYSE:HIMS)

Steward Partners Investment Advisory LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 2,770 shares of the company’s stock, valued at approximately $67,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Yong Rong HK Asset Management Ltd bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $41,104,000. Principal Financial Group Inc. grew its position in shares of Hims & Hers Health by 370.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock valued at $33,024,000 after acquiring an additional 1,075,355 shares during the period. Wellington Management Group LLP grew its position in shares of Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares during the period. Bank of New York Mellon Corp grew its position in shares of Hims & Hers Health by 128.7% during the 4th quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company’s stock valued at $30,103,000 after acquiring an additional 700,500 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after acquiring an additional 482,177 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America boosted their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday. Piper Sandler upped their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, Citigroup reaffirmed a “sell” rating and issued a $27.00 target price on shares of Hims & Hers Health in a report on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $37.31.

Hims & Hers Health Trading Down 9.3 %

Shares of NYSE:HIMS opened at $31.46 on Wednesday. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The company has a 50-day moving average price of $38.72 and a 200 day moving average price of $28.49. The company has a market cap of $6.99 billion, a price-to-earnings ratio of 71.49 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other news, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $26.00, for a total transaction of $195,000.00. Following the completion of the sale, the insider now owns 193,601 shares of the company’s stock, valued at approximately $5,033,626. The trade was a 3.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the sale, the insider now directly owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This represents a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,042,006 shares of company stock valued at $36,830,024 over the last 90 days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.